JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Recruiting now · Phase 3

Conditions studied: Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer

In brief

This Phase 3 study will evaluate the efficacy of JAB-21822+JAB-3312 versus tislelizumab (PD-1 Ab) combined with pemetrexed+carboplatin as the first line treatment in subjects with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).

Key facts

Study ID

NCT06416410

Run by

Allist Pharmaceuticals, Inc.

People needed

392

Starts

2024-08-07

Expected to finish

2027-02-28

Last updated by the study team

2025-04-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• A signed written informed consent is required before performing any study-related operations
• Age greater than or equal to 18 years old
• Histologically or cytologically confirmed locally advanced/metastatic, unresectable non-squamous NSCLC with KRAS p. G12C mutation confirmed by the central lab
• No history of systemic anticancer therapy to the local advanced/metastatic disease
• Expected survival period greater than or equal to 3 months
• Having at least one target lesion according to RECIST 1.1
• Eastern Cooperative Oncology Group (ECOG) ≤ 1

You may not qualify if…

• Previous (≤2 years) or current solid tumors or hematologic tumors of other pathological types
• Carry other driver gene mutations with available target therapy, or carry other KRAS mutations
• Subjects with untreated central nervous system (CNS) metastases were excluded;
• Uncontrolled pleural effusion, pericardial effusion, and ascites
• Subjects with impaired heart function or clinically significant heart disease

Where it is running

• Peking University Third Hospital — Beijing, Beijing Municipality, China (enrolling)
• Beijing Chest Hospital ,Capital Medical University — Beijing, Beijing Municipality, China (enrolling)
• Cangzhou hospital of integrated TCM-WM Hebei — Cangzhou, Hebei, China (enrolling)
• Cancer Hospital Chinese Academy Of Medical Sciences — Beijing, Beijing Municipality, China (enrolling)
• Beijing Cancer Hospital — Beijing, Beijing Municipality, China (enrolling)
• Shandong Cancer Hospital — Jinan, Shandong, China (enrolling)
• Guangxi Medical University Cancer hospital & Guangxi Cancer Institute — Nanning, Guangxi, China
• Harbin Medical University Cancer Hospital-Mammary gland of internal — Haerbin, Heilongjiang, China
• Henan Cancer Hospital — Zhengzhou, Henan, China
• The First Affiliated Hosipital Of Zhengzhou University — Zhengzhou, Henan, China
• Union Hospital Tongji Medical College Huazhong University of Science and Technology — Wuhan, Hubei, China
• Tongji Hospital Tongji Medical College of Hust — Wuhan, Hubei, China
• Hubei cancer hospital — Wuhan, Hubei, China
• Hunan Cancer Hospital — Changsha, Hunan, China
• Jiangsu province hospital — Nanjing, Jiangsu, China
• Wuxi People's Hospital — Wuxi, Jiangsu, China
• Jilin cancer hospital — Jilin City, Jilin, China
• The First Hospital Of China Medical University — Shenyang, Liaoning, China
• Liaoning Cancer Hospital & Institute — Shenyang, Liaoning, China
• LinYi Cancer Hospital — Linyi, Shandong, China
• The affiliated hospital of Qingdao university — Qingdao, Shandong, China
• Fudan University Shanghai Cancer Center — Shanghai, Shanghai Municipality, China
• Shanghai Pulmonary Hospital — Shanghai, Shanghai Municipality, China
• Shanxi province cancer hospital — Taiyuan, Shanxi, China
• The First Affiliated Hospital of Xi'An Jiaotong University — Xi’an, Shanxi, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.